20.37  -0.63 (-3%)		01-08 16:00
Open: 21.255 High: 21.56 Volume: 18,744		Pre. Close: 21 Low: 19.42 Market Cap: 33(M)

Short term
Mid term
Targets	6-month :	35.58	1-year :	44.76
Resists	First :	30.46	Second :	38.32
Pivot price	25.48
Supports	First :	17.75	Second :	14.76
MAs	MA(5) :	21.25	MA(20) :	26.72
	MA(100) :	13.2	MA(250) :	7.49
MACD	MACD :	-0.2	Signal :	1.2
%K %D	K(14,3) :	4.6	D(3) :	4.3
RSI	RSI(14): 42.2
52-week	High :	38.32	Low :	2

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ GLTO ] has closed above bottom band by 18.2%. Bollinger Bands are 40.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	21.6 - 21.72	21.72 - 21.86
Low:	19.1 - 19.23	19.23 - 19.36
Close:	20.12 - 20.35	20.35 - 20.6

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Tue, 06 Jan 2026
Biotech brings in cancer drug veterans as it readies new antibody trial - Stock Titan

Thu, 01 Jan 2026
Is the Market Bullish or Bearish on Galecto Inc? - Sahm

Sun, 21 Dec 2025
Galecto (GLTO) Price Target Increased by 12.50% to 36.72 - Nasdaq

Mon, 08 Dec 2025
Galecto (GLTO) Rating Maintained by Guggenheim, Price Target Rai - GuruFocus

Mon, 10 Nov 2025
Why Is Galecto Stock (GLTO) Up 285% Today? - TipRanks

Mon, 10 Nov 2025
GLTO, MOVE: two penny stocks quadrupled today – but should you buy? - TradingView — Track All Markets

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	3.5 (%)
Held by Institutions	46.3 (%)
Shares Short	181 (K)
Shares Short P.Month	337 (K)

EPS	-12.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.01
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-43.6 %
Return on Equity (ttm)	-109.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-7.42
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-1.69
PEG Ratio	0
Price to Book value	4.05
Price to Sales	0
Price to Cash Flow	-2.67

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.